- Home
- LXFR vs AVIR Comparison
LXFR vs AVIR Comparison
Compare LXFR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXFR
- AVIR
- Stock Information
- Founded
- LXFR 1898
- AVIR 2012
- Country
- LXFR United States
- AVIR United States
- Employees
- LXFR N/A
- AVIR N/A
- Industry
- LXFR Major Chemicals
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LXFR Industrials
- AVIR Health Care
- Exchange
- LXFR Nasdaq
- AVIR Nasdaq
- Market Cap
- LXFR 335.4M
- AVIR 290.4M
- IPO Year
- LXFR 2012
- AVIR 2020
- Fundamental
- Price
- LXFR $12.78
- AVIR $3.06
- Analyst Decision
- LXFR
- AVIR Hold
- Analyst Count
- LXFR 0
- AVIR 1
- Target Price
- LXFR N/A
- AVIR $6.00
- AVG Volume (30 Days)
- LXFR 98.8K
- AVIR 426.8K
- Earning Date
- LXFR 10-28-2025
- AVIR 11-06-2025
- Dividend Yield
- LXFR 4.07%
- AVIR N/A
- EPS Growth
- LXFR N/A
- AVIR N/A
- EPS
- LXFR 0.90
- AVIR N/A
- Revenue
- LXFR $403,800,000.00
- AVIR N/A
- Revenue This Year
- LXFR $3.12
- AVIR N/A
- Revenue Next Year
- LXFR $3.31
- AVIR N/A
- P/E Ratio
- LXFR $13.09
- AVIR N/A
- Revenue Growth
- LXFR 5.60
- AVIR N/A
- 52 Week Low
- LXFR $9.41
- AVIR $2.46
- 52 Week High
- LXFR $15.64
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- LXFR 42.67
- AVIR 45.69
- Support Level
- LXFR $12.57
- AVIR $2.99
- Resistance Level
- LXFR $13.74
- AVIR $3.17
- Average True Range (ATR)
- LXFR 0.42
- AVIR 0.12
- MACD
- LXFR -0.09
- AVIR 0.03
- Stochastic Oscillator
- LXFR 21.19
- AVIR 64.74
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).